stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Current ratio
ACADIA Pharmaceuticals Inc.'s current ratio at the end of the quarter to 30 September 2026 was 3.8×, down 0.0× from fiscal 2025 (3.8×). Over the past ten years it has ranged from 2.4× (fiscal 2024) to 12.9× (fiscal 2016); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.8× | 61.29% |
| FY2024 | 2.4× | (1.94%) |
| FY2023 | 2.4× | (40.06%) |
| FY2022 | 4.0× | (37.13%) |
| FY2021 | 6.4× | (5.04%) |
| FY2020 | 6.8× | (33.35%) |
| FY2019 | 10.2× | 15.03% |
| FY2018 | 8.8× | 15.95% |
| FY2017 | 7.6× | (40.80%) |
| FY2016 | 12.9× | 28.68% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.8× | 12.69% |
| Jun 2026 | 3.4× | (5.56%) |
| Mar 2026 | 3.6× | (6.41%) |
| Dec 2025 | 3.8× | 26.97% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| TNGX Tango Therapeutics, Inc. compare | 50.8× |
| IRON Disc Medicine, Inc. compare | 24.1× |
| XENE Xenon Pharmaceuticals Inc. compare | 21.0× |
| RLAY Relay Therapeutics, Inc. compare | 18.3× |
| PBLS Parabilis Medicines, Inc. compare | 17.9× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| IOVA Iovance Biotherapeutics, Inc. compare | 5.2× |
| ACAD ACADIA Pharmaceuticals Inc. | 3.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement